Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2023-181076

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Blood (2023) 142 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2023-179852

Published: 2023

Journal Articles

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4230.

https://doi.org/10.1182/blood-2023-185484

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

Blood (2023) 142 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2023-186687

Published: 2023

Journal Articles

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Blood (2022) 140 (Supplement 1): 7616–7618.

https://doi.org/10.1182/blood-2022-167051

Published: 2022

Journal Articles

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Blood (2022) 140 (Supplement 1): 4730–4732.

https://doi.org/10.1182/blood-2022-170498

Published: 2022

Journal Articles

Viral-Specific T Cell Therapy for Cytomegalovirus Infection after Stem Cell Transplantation and Generation of a Third-Party T-Cell Donor Registry

Pere Barba, Elisa Roldan, María Suárez-Lledó, Juan Montoro Gomez, Santiago Perez-Hoyos, Alberto Mussetti, Christelle Ferra, Ruth Coll, Luciano Rodriguez, Julia Marsal, Rodrigo Martino, Julio Castaño, Marga Codinach, Francesc Bosch, Ramon Gimeno, David Valcarcel, Francesc Rudilla, Sergio Querol

Blood (2022) 140 (Supplement 1): 10309–10310.

https://doi.org/10.1182/blood-2022-165943

Published: 2022

Journal Articles

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

María Queralt Salas, Paola Charry, Nuria Martínez-Cibrian, María Suárez-Lledó, Luis Gerardo Rodríguez-Lobato, Marc Brusosa, María Teresa Solano, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Jordi Arcarons, Noemí Llobet, Laura Rosinol Dachs, Jordi Esteve, Álvaro Urbano-Ispizua, Enric Carreras, Francesc Fernández-Avilés, Maria Carmen Martinez Munoz, Montserrat Rovira

Blood (2022) 140 (Supplement 1): 4772–4773.

https://doi.org/10.1182/blood-2022-170407

Published: 2022

Journal Articles

Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells

Anthony M Battram, Aina Oliver-Caldés, Miquel Bosch i Crespo, María Suárez-Lledó, Miquel Lozano, Nuria Martínez-Cibrian, Joan Cid, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 480.

https://doi.org/10.1182/blood-2021-147774

Published: 2021

Journal Articles

Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Paola Andrea Charry, Maria Queralt Salas, Alexandra Pedraza, María Suárez-Lledó, Nuria Martínez-Cibrian, Teresa Solano, Ariadna Domenech, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Laura Rosinol, Francesc Fernández-Avilés, Gonzalo Gutiérrez-García, Enric Carreras, Jordi Esteve, Álvaro Urbano-Ispizua, Montserrat Rovira, Carmen Martínez

Blood (2021) 138 (Supplement 1): 2760.

https://doi.org/10.1182/blood-2021-153366

Published: 2021

Journal Articles

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

Blood (2021) 138 (Supplement 1): 3925.

https://doi.org/10.1182/blood-2021-153069

Published: 2021

Journal Articles

COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)

Per Ljungman, MD PhD, Rafael De La Camara, MD, Malgorzata Mikulska, Gloria Tridello, Beatriz Aguado, MD, Yves Beguin, MD PhD, Rodrigo Martino Bufarull, Fabio Ciceri, MD, Lucía López Corral, MD, Claudia Crippa, MD, Dries Deeren, MD PhD, Rafael F. Duarte, MD PhD FRCP, María Laura Fox, Anna Grassi, MD, María-José Jimenez, MD, Safiye Koculu, MD, Mi Kwon, MD PhD, Juan Carlos Vallejo Llamas, Jose Luiz Lopez Lorenzo, MD, Stephan Mielke, MD, Javier López Jiménez, MD PhD, Zoraida Mesa Morales, Kim H. Orchard, MBBS,PhDFRCP,FRCPath, Rocio Parody Porras, Victoria Potter, MBBS, BSc, FRACP, FRCPA, María Suárez-Lledó, MD, Nicolaas Schaap, MD PhD, Celestine Simand, MD, Luisa Sisinni, MD, John A Snowden, MD PhD, Daniele Vallisa, MD, Ipek Yonalhindilerden, Alienor Xhaard, MD, Nina Simone Knelange, Angel Cedillo, Nicolaus Kröger, MD, Jose Luis Piñana Sanchez, Jan Styczynski, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-138732

Published: 2020

Journal Articles

Post-Transplant High-Dose Cyclophosphamide Overcomes the Detrimental Effect of a Single-Locus HLA Mismatched in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Patricia Ferraz, MD, Arturo Pereira, MD PhD, María Suárez-Lledó, MD, Gonzalo Gutiérrez-García, MD, Francesc Fernández-Avilés, MD, Laura Rosinol, MD PhD, Teresa Solano, Noemí Llobet, Carla Ramos, Pedro Marín, MD, Alvaro Urbano-Ispizua, MD, Montserrat Rovira, MD, Carmen Martinez, MD PhD

Blood (2018) 132 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2018-99-112985

Published: 2018

Journal Articles

Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

Nuria Martinez-Cibrian, Teresa Garrido, Arturo Pereira, Mauricio Sarmiento, Jose Antonio Pérez-Simón, Rocio Parody, MD, Estefania Perez, Oriana Lopez, Carlos Solano, Jose Luis Piñana, Montserrat Rovira, Francesc Fernandez-Avilés, Maria Suarez-Lledo, Alvaro Urbano-Ispizua, Carmen Martinez, MD PhD

Blood (2015) 126 (23): 5464.

https://doi.org/10.1182/blood.V126.23.5464.5464

Published: 2015

Journal Articles

Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution

Marina Diaz-Beya, MD PhD, Miguel Angel Torrente, Alfonso Ardilla, Carles Serra, Nuria Martinez, Maria Suarez-Lledo, Carmen Martinez, Francesc Fernandez, Laura Rosiñol, Gonzalo Gutierrez, Pedro Marin, Marta Pratcorona, Nuria Mariegues, Noemi Llobet, Marta Bistagne, Enric Carreras, Alvaro Urbano-Ispizua, Montserrat Rovira, Jordi Esteve, MD PhD

Blood (2015) 126 (23): 4395.

https://doi.org/10.1182/blood.V126.23.4395.4395

Published: 2015

Journal Articles

Allogeneic Stem-Sell Transplantation In Multiple Myeloma In Real Practice: Long-Term Results From a Single Institution

Raquel Jiménez, MD, Laura Rosiñol, MD, Montserrat Rovira, MD, Francisco Fernández-Avilés, Carmen Martínez, MD, Gonzalo Gutiérrez-García, Maria Suárez-LLedó, Carlos Fernández De Larrea, MD, Alvaro Urbano, MD, Joan Blade, MD

Blood (2013) 122 (21): 5524.

https://doi.org/10.1182/blood.V122.21.5524.5524

Published: 2013

Journal Articles

A Gene Variant in IRF3 Impacts On the Clinical Outcome of Acute Myeloid Leukemia (AML) Patients Submitted to Allogeneic Stem Cell Transplantation (allo-SCT)

Beatriz Martin-Antonio, Ph.D., Maria Suarez-LLedo, Montserrat Arroyes, Francesc Fernandez-Avilés, Carmen Martinez, MD, Montserrat Rovira, Ildefonso Espigado, MD, PhD, David Gallardo, MD, PhD, Anna Bosch, Ismael Buno, PhD, Carolina Martinez-Laperche, PhD, Antonio Jimenez-Velasco, Rafael De La Camara, MD, Salut Brunet, Jose B. Nieto, Alvaro Urbano-Ispizua, MD/Ph.D

Blood (2012) 120 (21): 468.

https://doi.org/10.1182/blood.V120.21.468.468

Published: 2012

Journal Articles

G to C Transition At Position −173 of MIF Gene Associates with Poor Survival in Acute Myeloid Leukemia Patients and After Allogeneic Stem Cell Transplantation (Allo-SCT)

Blood (2011) 118 (21): 2530.

https://doi.org/10.1182/blood.V118.21.2530.2530

Published: 2011

Journal Articles

A Recessive Gene Variant in TGFB1 in the Donor Influences the Acute Graft Versus Host Disease Development and Impacts in the Outcome After Allogeneic Stem Cell Transplantation (Allo-SCT),

Beatriz Martin-Antonio, Damià Romero, Ildefonso Espigado, MD, PhD, David Gallardo, MD, PhD, Anna Bosch, Ismael Buno, Carolina Martinez-Laperche, Antonio Jimenz-Velasco, Rafael De La Camara, MD, Salut Brunet, Jose B Nieto, Jose Román, Maria Suarez-LLedo, Francesc Fernandez-Avilés, Carmen Martinez, MD, Montserrat Rovira, Alvaro Urbano-Ispizua, MD

Blood (2011) 118 (21): 4080.

https://doi.org/10.1182/blood.V118.21.4080.4080

Published: 2011

NARROW

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Viral-Specific T Cell Therapy for Cytomegalovirus Infection after Stem Cell Transplantation and Generation of a Third-Party T-Cell Donor Registry

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells

Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)

Post-Transplant High-Dose Cyclophosphamide Overcomes the Detrimental Effect of a Single-Locus HLA Mismatched in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution

Allogeneic Stem-Sell Transplantation In Multiple Myeloma In Real Practice: Long-Term Results From a Single Institution

A Gene Variant in IRF3 Impacts On the Clinical Outcome of Acute Myeloid Leukemia (AML) Patients Submitted to Allogeneic Stem Cell Transplantation (allo-SCT)

G to C Transition At Position −173 of MIF Gene Associates with Poor Survival in Acute Myeloid Leukemia Patients and After Allogeneic Stem Cell Transplantation (Allo-SCT)

A Recessive Gene Variant in TGFB1 in the Donor Influences the Acute Graft Versus Host Disease Development and Impacts in the Outcome After Allogeneic Stem Cell Transplantation (Allo-SCT),

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only